Compare Amphastar Pharmaceuticals Inc (AMPH) vs Transocean Ltd (RIG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Transocean Ltd — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Transocean Ltd trades at $5.27 (market cap $5.76B). The key difference: Transocean Ltd is far larger — about 7× Amphastar Pharmaceuticals Inc's market cap, and Transocean Ltd is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | RIG | |
|---|---|---|
Market Cap | $826.08M | $5.76B |
Sector | Health | Technology |
52-Week High | $30.81 | $7.58 |
52-Week Low | $16.87 | $2.55 |
Enterprise Value | $1.22B | $10.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Transocean Ltd. (RIG) trades at $5.20, up 1.17% today, with a bearish technical signal and mixed earnings history. The company reported a net loss of -$2.92 billion for 2025 but maintains strong revenue of $3.97 billion and a gross margin of 84.88%. Recent news highlights a $1 billion contract with Equinor and a pending merger with Valaris, aimed at reducing leverage and unlocking synergies.
The outlook is cautiously optimistic, with analyst consensus pointing to a $7.00 price target and 39% buy ratings. Key opportunities include backlog growth and merger benefits, while risks involve persistent net losses, oil price volatility, and execution challenges. The stock's valuation appears attractive with a P/B of 0.7, but profitability remains a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
